⌕
Dyne Therapeutics · DYN · Nasdaq
Tenet 52 · Mixed
Compare
$16.02−4.07%At closeTenet 52 · Mixed
$16.02−0.68 (−4.07%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Dyne Therapeutics (DYN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is DYN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 01:44 ET
Dyne Therapeutics (NASDAQ:DYN) Share Price Breaks Below 50-Day Moving Average on Insider Selling

Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day moving average of $16…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Dyne Therapeutics to Participate in Upcoming Investor Conference

WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular dise…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular disea…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural histor…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireSep 17, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular dise…

DYN −4.1% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 12:21 ET
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

DYN −4.1% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 07:45 ET
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class

Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targetin…

DYN −4.1% todayRead at source ↗
● Defense WorldSep 9, 2026 · 01:21 ET
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)

Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors bought 20,532 call options on the stock. This is an increase of 4,325% compared to the aver…

DYN −4.1% todayRead at source ↗
● BenzingaSep 8, 2026 · 13:40 ET
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 07:51 ETCOMPANY'S OWN WORDS
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort -…

DYN −4.1% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:23 ETEARNINGS EXPECTED BY FEB 3
Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC’s 2nd Largest Position

Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 25.5% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commissi…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverag…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular dis…

DYN −4.1% todayRead at source ↗
● Defense WorldAug 26, 2026 · 03:57 ETEARNINGS EXPECTED BY FEB 3
ADAR1 Capital Management LLC Buys Shares of 42,821 Dyne Therapeutics, Inc. $DYN

ADAR1 Capital Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commiss…

DYN −4.1% todayRead at source ↗
● Defense WorldAug 25, 2026 · 04:18 ETEARNINGS EXPECTED BY FEB 3
242,392 Shares in Dyne Therapeutics, Inc. $DYN Acquired by Deutsche Bank AG

Deutsche Bank AG purchased a new position in Dyne Therapeutics, Inc. (NASDAQ: DYN) in a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institu…

DYN −4.1% todayRead at source ↗
● GlobeNewsWireAug 20, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular disea…

DYN −4.1% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA34−0.4%
DLB4−3.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just DYN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.